TREAT Act

Bill: 117-hr-5663
Sponsor: full_name: Rep. Harshbarger, Diana [R-TN-1]
Introduced: 2021-10-21
Policy area: Health
Subjects: Cardiovascular and respiratory health

Drug therapy

Emergency medical services and trauma care

Health care coverage and access

Health facilities and institutions

Health technology, devices, supplies

Immunology and vaccination

Infectious and parasitic diseases

State and local government operations
Latest action: action_date: 2021-10-22
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2021-10-21
action_desc: Introduced in House
text: <p><strong>Treatment Restoration for Emergency Antibody Therapeutics Act or the TREAT Act</strong></p> <p>This bill prohibits the Department of Health and Human Services (HHS) from implementing any policy that restricts health care facilities from ordering and receiving COVID-19 monoclonal antibody therapies directly from manufacturers and distributors. In addition, the bill expressly nullifies a policy announced on September 13, 2021, under which HHS allocated supplies of these therapies through state or territorial governments.</p>

tv_txt: I 117th CONGRESS 1st Session H. R. 5663 IN THE HOUSE OF REPRESENTATIVES October 21, 2021 Mrs. Harshbarger (for herself, Mr. DesJarlais , Mr. Burchett , Mr. Fleischmann , Mr. Posey , Mr. Babin , Mrs. Cammack , Mr. Roy , Mr. Rose , Mrs. Miller-Meeks , Mr. Perry , Mr. Gohmert , Mr. Mast , Mr. Steube , Mr. Jackson , Mr. Williams of Texas , Mr. Austin Scott of Georgia , and Mr. Donalds ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To prohibit the Secretary of Health and Human Services from restricting direct access by health care facilities to COVID–19 monoclonal antibody therapies.

1. Short title This Act may be cited as the Treatment Restoration for Emergency Antibody Therapeutics Act or the TREAT Act . 2. Prohibition on restrictions on direct access to COVID–19 monoclonal antibody therapies (a) In general Notwithstanding any other provision of law, the Secretary of Health and Human Services (referred to in this section as the Secretary ) may not implement or continue in effect any policy that would restrict hospitals or other appropriate health care facilities from ordering and receiving COVID–19 monoclonal antibody therapies directly from manufacturers and distributors of such therapies. (b) Nullification of certain policy Pursuant to subsection (a), effective on the date of enactment of this Act, the policy under which the Secretary required hospitals and other facilities to work through State or territorial governments to receive supplies of COVID–19 monoclonal antibody therapies allocated by the Secretary to such States or territories, announced by such Secretary on September 13, 2021, shall have no force or effect.